Omega-3 Fatty Acids in Perimenopause: What the Evidence Shows

Omega-3 fatty acids are among the most widely studied dietary supplements, yet their specific role in the menopause transition is often oversimplified. They are not a hormone-balancing cure, but they do have well-characterised effects on cardiovascular risk, inflammation, and mood—systems that all undergo meaningful change during perimenopause. Understanding what the evidence actually supports helps you decide whether and how to use them.

What omega-3 fatty acids are and where they come from

Omega-3s are a family of polyunsaturated fatty acids. The two most clinically relevant are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), found primarily in oily fish and fish oil supplements. A third, ALA (alpha-linolenic acid), is found in plant foods such as flaxseed, chia seeds, and walnuts, but the body converts ALA to EPA and DHA inefficiently—meaning plant-only sources may not achieve the tissue levels associated with clinical benefit. Algae-derived omega-3 supplements provide EPA and DHA directly and are a practical option for people who do not eat fish.

• Oily fish (salmon, mackerel, sardines, herring, anchovies): 1–3 g of EPA+DHA per 100 g serving.
• Fish oil capsules: dose varies widely; check the EPA+DHA content rather than the total fish oil weight on the label.
• Algae-derived omega-3: provides DHA and sometimes EPA; a practical alternative for vegetarians and vegans.
• ALA sources (flaxseed, chia, walnuts): contribute to overall intake but are poor substitutes for EPA+DHA.

Cardiovascular health: where the evidence is strongest

Cardiovascular risk increases after the final menstrual period, partly because oestrogen's vasculoprotective effects diminish and LDL cholesterol, triglycerides, and blood pressure trends worsen. Omega-3s—particularly at higher prescription doses—have a well-established triglyceride-lowering effect, with reductions of 20–30% documented in randomised trials. The REDUCE-IT trial found that high-dose icosapentaenoic acid (EPA, 4 g daily in the form of icosapent ethyl) significantly reduced major cardiovascular events in people with elevated triglycerides on a statin, though that dose and formulation is prescription-only. Standard fish oil supplements at typical consumer doses (1–2 g total omega-3 per day) have a more modest effect and are better framed as dietary support than as a cardiovascular treatment.

Hot flashes, mood, and brain health

Several randomised trials have examined omega-3s and vasomotor symptoms with mixed results. A 2009 Canadian trial found that EPA supplementation (1.8 g daily) reduced hot flash frequency by approximately 55% compared with placebo, but subsequent studies have not consistently replicated this. The current weight of evidence does not support omega-3s as a reliable standalone treatment for hot flashes; they may be a useful adjunct in women who also have elevated triglycerides or mood symptoms, where multiple benefits converge.

The evidence for omega-3s and depression is more consistent. Several meta-analyses of randomised trials show a modest but statistically significant antidepressant effect, particularly for EPA-dominant formulations at doses above 1 g of EPA per day. For women experiencing low mood during the menopause transition—a period when rates of first-onset and recurrent depression rise—this is a reasonable discussion point with a clinician, alongside (not instead of) evidence-based treatments for depression.

Joint pain and dry skin: biologically plausible, evidence modest

Omega-3s are precursors to anti-inflammatory eicosanoids, and this mechanism supports their use in inflammatory joint conditions such as rheumatoid arthritis, where clinical evidence is reasonably consistent. The inflammation that contributes to perimenopause-related joint aching is less well characterised, and dedicated trial evidence in this context is limited. Similarly, DHA is a structural component of cell membranes throughout the body, including skin, and there is some evidence that EPA and DHA supplementation improves skin hydration and barrier function—relevant given that dry skin is a commonly reported perimenopausal symptom. The evidence here is suggestive rather than conclusive.

Dosing, safety, and things to discuss with your clinician

Standard dietary guidance recommends two portions of oily fish per week, equivalent to approximately 0.5 g EPA+DHA per day. Consumer omega-3 supplements typically contain 250–500 mg of EPA+DHA per capsule; doses used in clinical research for mood or triglyceride effects are generally 1–4 g of EPA+DHA daily. At standard consumer doses, fish oil is considered safe for most adults. At higher doses or in people taking anticoagulants (warfarin, rivaroxaban) or antiplatelet agents (aspirin, clopidogrel), there is a theoretical increased bleeding risk; this should be discussed with a clinician before starting supplementation.

• Choose a supplement that states the EPA and DHA content per serving, not just total fish oil.
• Store fish oil capsules in the fridge to reduce oxidation and rancidity.
• A fishy aftertaste can be reduced by taking capsules with a meal or choosing enteric-coated products.
• If you take blood thinners or have a clotting disorder, consult your clinician before supplementing.
• Pregnancy doses and upper limits differ from general adult guidance—seek specific advice if applicable.